Cardiovascular Ultrasound Market is expected to be worth US$ 2.6 billion by 2032 | FMI

 The Cardiovascular Ultrasound Market revenues were estimated at US$ 1.2 Billion in 2021 and is anticipated to grow at a CAGR of 7.2% from 2022-2032, according to a recently published Future Market Insights report. By the end of 2032, the market is expected to reach US$ 2.6 Billion.

Cardiovascular Ultrasound Market


The market is predicted to grow as preventative medicine becomes more widely used and the prevalence of Cardiovascular Diseases (CVDs) rises. Outpatient imaging services were negatively impacted by the COVID-19 pandemic, which impeded global market growth.

Get Complete Access: https://www.futuremarketinsights.com/reports/cardiovascular-ultrasound-market

Coronary heart disease, heart attack, and stroke are among the most common causes of death in the United States. CVD predisposition has grown as a result of changing lifestyles. According to the CDC, 28.2 million persons in the United States were diagnosed with heart disease in 2017. Ultrasound technology is used to check for anomalies in the heart's function, such as cardiac pumping capacity, valve function, and plaque in the heart.

Ultrasound imaging is a noninvasive medical diagnostic tool that helps doctors diagnose and treat medical issues. The images of the veins and arteries in the body are produced by vascular ultrasonography.

A Doppler ultrasound scan is often part of a vascular ultrasound evaluation. They can also show blood flowing through arteries. The global cardiovascular ultrasound treatment market is being driven by factors such as the rising prevalence of heart diseases and the growing acceptability of cardiovascular ultrasound systems over older invasive cardiac diagnostic procedures.

Competitive Landscape

Some of the prominent players in the cardiovascular ultrasound market include GE Healthcare, Koninklijke Philips, Siemens Healthineers AG, Hitachi Medical Corp., Samsung Medison Co. Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Chison Wuxi Xiangsheng Medical Technology Co., Ltd., and Fujifilm Sonosite, Inc.

Some of the recent developments of key Cardiovascular Ultrasound providers are as follows:

  • In October 2020, GE Healthcare got FDA 510k clearance for their extreme edition package of vivid cardiovascular ultrasound devices, which contains new artificial intelligence (AI)-based features that enable doctors to obtain faster, more consistent assessments.
  • In October 2020, Royal Philips introduced the Ultrasound 3300 in India. OB/GYN, cardiovascular imaging, and general imaging are a few of the applications for the device.
  • In August 2020, Philips announced the release of its new Affiniti CVx and 7.0 for EPIQ CVx cardiovascular ultrasound systems, which include enhancements to boost diagnostic confidence and improve the user experience.

Market Segments Covered in Cardiovascular Ultrasound Market Analysis

By Type:

  • Fetal Echocardiography
  • Transthoracic Echocardiography
  • Transesophageal Echocardiography
  • Others

By Technology:

  • 2D
  • 3D/4D
  • Doppler

By Display Type:

  • B/W
  • Color

By End-use:

  • Hospitals
  • Diagnostic Centers
  • Ambulatory Care Centers
  • Other End-uses

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Primary Sclerosing Cholangitis (PSC) Market Size, Opportunities and Forecast 2023-2033

Image
  The global Primary Sclerosing Cholangitis (PSC) Market is anticipated to be worth US$ 151.07 million in 2023.  Primary Sclerosing Cholangitis (PSC) With growing alcohol consumption, the worldwide market for Primary Sclerosing Cholangitis (PSC) is expected to develop at a CAGR of 7.6% between 2023 and 2033, totaling roughly US$ 314.26 Million by 2033. According to the analysis of Future Market Insights, the Primary Sclerosing Cholangitis (PSC) market is expected to fuel over the analysis period, attributed to the factors such as the rise in the incidences of liver diseases, as well as rise in alcohol consumption. Get Full Access @ https://www.futuremarketinsights.com/reports/primary-sclerosing-cholangitis-psc-market  As per the Centers for Disease Control and Prevention, the global incidence of liver disease was 3.9 million in 2016. As per the World Health Organization (WHO), prevalence of liver cirrhosis is increasing in the European countries, due to high con...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more